Roche Launches New Global Phase 3 Trial for Elevidys, Revitalizing Bid for European Approval of Duchenne Gene Therapy
admin The Swiss pharmaceutical giant Roche has announced the initiation of a new global Phase 3...
drug development
Eli Lilly’s Foundayo Achieves Cardiovascular Safety Milestone, Paving Way for Diabetes Approval Amidst Broader GLP-1 Market Expansion
Eli Lilly and Company’s oral obesity drug, Foundayo, has successfully met its primary objective in...
Trump Nominates Erica Schwartz to Lead Tumultuous CDC Amidst Public Health Policy Overhaul
President Donald Trump on Thursday announced his nomination of Erica Schwartz, a prominent public health...
Big Pharma CEOs Defy Market Trends with Soaring Multi-Million Dollar Compensation Packages in 2025 Amidst Strategic Triumphs and Public Scrutiny
While chief executives at S&P 500 companies generally experienced a median salary increase of approximately...
UCB, betting on seizure cell therapy, to buy Neurona for up to $1.2B
Belgian biopharmaceutical giant UCB announced Friday a definitive agreement to acquire Neurona Therapeutics, a privately...
Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool
The biopharmaceutical landscape witnessed a flurry of significant developments this past week, ranging from the...
Kailera Therapeutics Secures $625 Million in Landmark Biotech IPO, Igniting Competition in the Obesity Drug Market
Kailera Therapeutics, a formidable new entrant in the pharmaceutical landscape poised to challenge industry giants...
FDA Plans Advisory Committee Meetings on Peptide Reclassification Amidst Political Scrutiny and Calls for Regulatory Clarity
The Food and Drug Administration (FDA) is set to convene a series of advisory committee...
Eli Lilly’s Foundayo Faces Post-Approval FDA Scrutiny Over Liver Safety Data from Ongoing Diabetes Trial.
Eli Lilly’s newly approved oral obesity medication, Foundayo (orforglipron), has been subjected to significant post-market...
Terremoto raises $108M to pursue development of drugs targeting AKT
California-based Terremoto Biosciences has successfully closed a substantial $75 million Series A financing round, positioning...
